KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Asset Writedowns and Impairment (2018 - 2025)

Novavax (NVAX) has 6 years of Asset Writedowns and Impairment data on record, last reported at $1.5 million in Q4 2025.

  • For Q4 2025, Asset Writedowns and Impairment fell 63.75% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $4.9 million, up 18.1%, while the annual FY2025 figure was $4.9 million, 18.1% up from the prior year.
  • Asset Writedowns and Impairment reached $1.5 million in Q4 2025 per NVAX's latest filing, down from $3.0 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $10.1 million in Q2 2023 and bottomed at -$1.7 million in Q3 2024.
  • Average Asset Writedowns and Impairment over 3 years is $2.7 million, with a median of $1.7 million recorded in 2024.
  • The widest YoY moves for Asset Writedowns and Impairment: up 281.73% in 2025, down 63.75% in 2025.
  • A 3-year view of Asset Writedowns and Impairment shows it stood at $10.1 million in 2023, then tumbled by 59.01% to $4.1 million in 2024, then tumbled by 63.75% to $1.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Asset Writedowns and Impairment were $1.5 million in Q4 2025, $3.0 million in Q3 2025, and $349000.0 in Q2 2025.